+关注
___遇见倾橙____馨
暂无个人介绍
IP属地：江西
13
关注
0
粉丝
2
主题
0
勋章
主贴
热门
___遇见倾橙____馨
2022-08-02
这篇文章不错，转发给大家看
@腾盛博药2137HK:引领中国科技创新，腾盛博药被评为《麻省理工科技评论》50家聪明公司之一
___遇见倾橙____馨
2022-06-27
$腾盛博药-B(02137)$
起飞了
___遇见倾橙____馨
2022-06-17
$腾盛博药-B(02137)$
现在止跌了，提前埋伏好来，这票出来这么多的利好消息，迟迟不涨，主力又在折磨人呢，大家得有耐心等待
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3584009843426391","uuid":"3584009843426391","gmtCreate":1620985010053,"gmtModify":1620985800132,"name":"___遇见倾橙____馨","pinyin":"yjqcxyujianqingchengxin","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/5a3f250c18c42689db56196292cad8ab","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":13,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":2,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.09","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.70%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.01","exceedPercentage":"60.90%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"江西","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":685975067,"gmtCreate":1659419949360,"gmtModify":1659419949360,"author":{"id":"3584009843426391","authorId":"3584009843426391","name":"___遇见倾橙____馨","avatar":"https://static.tigerbbs.com/5a3f250c18c42689db56196292cad8ab","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584009843426391","authorIdStr":"3584009843426391"},"themes":[],"htmlText":"这篇文章不错，转发给大家看","listText":"这篇文章不错，转发给大家看","text":"这篇文章不错，转发给大家看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/685975067","repostId":"682495624","repostType":1,"repost":{"id":682495624,"gmtCreate":1659098820000,"gmtModify":1659101103758,"author":{"id":"4088222930030430","authorId":"4088222930030430","name":"腾盛博药2137HK","avatar":"https://static.tigerbbs.com/7225daebeee9c083bcbed970259d2446","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088222930030430","authorIdStr":"4088222930030430"},"themes":[],"title":"引领中国科技创新，腾盛博药被评为《麻省理工科技评论》50家聪明公司之一","htmlText":"7月29日，《麻省理工科技评论》2021年度50家聪明公司（TR50）榜单重磅揭晓，腾盛博药凭借其创新的研发管线，以及其在新冠中和抗体药物研发上的重大突破荣登榜单。此次年度榜单评选以“可持续未来”概念为导向，聚焦“在中国诞生的、由中国引领的、为中国服务”的创新力量，从而预见未来有能力引领中国和世界科技发展浪潮的企业。该榜单汇聚了在中国具有科技创新影响力，看重中国未来潜力，并且积极布局并服务中国市场的公司。腾盛博药自创立至今，始终践行以突破性的创新和洞察应对最严峻公共卫生挑战的使命，致力于针对患者未被满足的需求和重大公共卫生性疾病开发创新疗法。公司布局乙肝、新冠、艾滋病等多种重大传染性病领域。其中，其新冠中和抗体安巴韦单抗和罗米司韦单抗联合疗法作为中国首个获批的新冠中和抗体药物，仅用了27个月的时间就从最初的开发推进到商业化上市，为我国疫情防控做出重大贡献。《麻省理工科技评论》自1899年诞生起，长期关注创新科技的商业化和资本化进程，不仅见证了百年岁月中跌宕起伏的产业变迁，也参与了一代又一代新技术浪潮引发的时代变革。2010年开始，《麻省理工科技评论》每年都会从全球万千科技公司中遴选出“50 家聪明公司”（50 Smartest Companies，TR50），以此洞见未来科技大势。点击下图浏览完整榜单关于腾盛博药腾盛博药生物科技有限公司（“腾盛博药”；股份代号：2137.HK）是一家位于中国及美国的生物技术公司，致力于针对中国及全球重大感染性疾病（如乙型肝炎、COVID-19、人类免疫缺陷病毒 (HIV) 感染、多重耐药 (MDR) 或广泛耐药性 (XDR) 革兰氏阴性菌感染）及其它具有重大公共卫生负担的疾病（如中枢神经系统 (CNS) 疾病）开发创新疗法。阅读原文文章原文","listText":"7月29日，《麻省理工科技评论》2021年度50家聪明公司（TR50）榜单重磅揭晓，腾盛博药凭借其创新的研发管线，以及其在新冠中和抗体药物研发上的重大突破荣登榜单。此次年度榜单评选以“可持续未来”概念为导向，聚焦“在中国诞生的、由中国引领的、为中国服务”的创新力量，从而预见未来有能力引领中国和世界科技发展浪潮的企业。该榜单汇聚了在中国具有科技创新影响力，看重中国未来潜力，并且积极布局并服务中国市场的公司。腾盛博药自创立至今，始终践行以突破性的创新和洞察应对最严峻公共卫生挑战的使命，致力于针对患者未被满足的需求和重大公共卫生性疾病开发创新疗法。公司布局乙肝、新冠、艾滋病等多种重大传染性病领域。其中，其新冠中和抗体安巴韦单抗和罗米司韦单抗联合疗法作为中国首个获批的新冠中和抗体药物，仅用了27个月的时间就从最初的开发推进到商业化上市，为我国疫情防控做出重大贡献。《麻省理工科技评论》自1899年诞生起，长期关注创新科技的商业化和资本化进程，不仅见证了百年岁月中跌宕起伏的产业变迁，也参与了一代又一代新技术浪潮引发的时代变革。2010年开始，《麻省理工科技评论》每年都会从全球万千科技公司中遴选出“50 家聪明公司”（50 Smartest Companies，TR50），以此洞见未来科技大势。点击下图浏览完整榜单关于腾盛博药腾盛博药生物科技有限公司（“腾盛博药”；股份代号：2137.HK）是一家位于中国及美国的生物技术公司，致力于针对中国及全球重大感染性疾病（如乙型肝炎、COVID-19、人类免疫缺陷病毒 (HIV) 感染、多重耐药 (MDR) 或广泛耐药性 (XDR) 革兰氏阴性菌感染）及其它具有重大公共卫生负担的疾病（如中枢神经系统 (CNS) 疾病）开发创新疗法。阅读原文文章原文","text":"7月29日，《麻省理工科技评论》2021年度50家聪明公司（TR50）榜单重磅揭晓，腾盛博药凭借其创新的研发管线，以及其在新冠中和抗体药物研发上的重大突破荣登榜单。此次年度榜单评选以“可持续未来”概念为导向，聚焦“在中国诞生的、由中国引领的、为中国服务”的创新力量，从而预见未来有能力引领中国和世界科技发展浪潮的企业。该榜单汇聚了在中国具有科技创新影响力，看重中国未来潜力，并且积极布局并服务中国市场的公司。腾盛博药自创立至今，始终践行以突破性的创新和洞察应对最严峻公共卫生挑战的使命，致力于针对患者未被满足的需求和重大公共卫生性疾病开发创新疗法。公司布局乙肝、新冠、艾滋病等多种重大传染性病领域。其中，其新冠中和抗体安巴韦单抗和罗米司韦单抗联合疗法作为中国首个获批的新冠中和抗体药物，仅用了27个月的时间就从最初的开发推进到商业化上市，为我国疫情防控做出重大贡献。《麻省理工科技评论》自1899年诞生起，长期关注创新科技的商业化和资本化进程，不仅见证了百年岁月中跌宕起伏的产业变迁，也参与了一代又一代新技术浪潮引发的时代变革。2010年开始，《麻省理工科技评论》每年都会从全球万千科技公司中遴选出“50 家聪明公司”（50 Smartest Companies，TR50），以此洞见未来科技大势。点击下图浏览完整榜单关于腾盛博药腾盛博药生物科技有限公司（“腾盛博药”；股份代号：2137.HK）是一家位于中国及美国的生物技术公司，致力于针对中国及全球重大感染性疾病（如乙型肝炎、COVID-19、人类免疫缺陷病毒 (HIV) 感染、多重耐药 (MDR) 或广泛耐药性 (XDR) 革兰氏阴性菌感染）及其它具有重大公共卫生负担的疾病（如中枢神经系统 (CNS) 疾病）开发创新疗法。阅读原文文章原文","images":[{"img":"https://static.tigerbbs.com/d820fd0756294c92ba1a5a01063ce48f"},{"img":"https://static.tigerbbs.com/625356db2ee84948a5932a128615e8fd","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/27a9fabd27f042e4a5125df29b901e14","width":"-1","height":"-1"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/682495624","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":5,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":987,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":683619409,"gmtCreate":1656297478603,"gmtModify":1704864345915,"author":{"id":"3584009843426391","authorId":"3584009843426391","name":"___遇见倾橙____馨","avatar":"https://static.tigerbbs.com/5a3f250c18c42689db56196292cad8ab","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584009843426391","authorIdStr":"3584009843426391"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02137\">$腾盛博药-B(02137)$</a>起飞了","listText":"<a href=\"https://laohu8.com/S/02137\">$腾盛博药-B(02137)$</a>起飞了","text":"$腾盛博药-B(02137)$起飞了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/683619409","isVote":1,"tweetType":1,"viewCount":571,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":689128241,"gmtCreate":1655434200384,"gmtModify":1704862347210,"author":{"id":"3584009843426391","authorId":"3584009843426391","name":"___遇见倾橙____馨","avatar":"https://static.tigerbbs.com/5a3f250c18c42689db56196292cad8ab","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584009843426391","authorIdStr":"3584009843426391"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02137\">$腾盛博药-B(02137)$</a>现在止跌了，提前埋伏好来，这票出来这么多的利好消息，迟迟不涨，主力又在折磨人呢，大家得有耐心等待","listText":"<a href=\"https://laohu8.com/S/02137\">$腾盛博药-B(02137)$</a>现在止跌了，提前埋伏好来，这票出来这么多的利好消息，迟迟不涨，主力又在折磨人呢，大家得有耐心等待","text":"$腾盛博药-B(02137)$现在止跌了，提前埋伏好来，这票出来这么多的利好消息，迟迟不涨，主力又在折磨人呢，大家得有耐心等待","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/689128241","isVote":1,"tweetType":1,"viewCount":1689,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000310","authorId":"9000000000000310","name":"迪士尼迪斯尼","avatar":"https://static.tigerbbs.com/d08ad56d0cf912758e58222fffc1f75b","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000310","authorIdStr":"9000000000000310"},"content":"总市值 58.9亿 成交量 364.00万 市盈率TTM -0.73 流通市值 58.9亿 股息 -- 市盈率LYR -0.73 总股本 7.23亿 股息收益率 -- 每股收益TTM -11.10 流通股本 7.23亿 ROA -15.64% 每股收益LYR -11.10 52周最高 52.600 ROE -534.39% 市净率 1.51，财报数据看着有点不好看","text":"总市值 58.9亿 成交量 364.00万 市盈率TTM -0.73 流通市值 58.9亿 股息 -- 市盈率LYR -0.73 总股本 7.23亿 股息收益率 -- 每股收益TTM -11.10 流通股本 7.23亿 ROA -15.64% 每股收益LYR -11.10 52周最高 52.600 ROE -534.39% 市净率 1.51，财报数据看着有点不好看","html":"总市值 58.9亿 成交量 364.00万 市盈率TTM -0.73 流通市值 58.9亿 股息 -- 市盈率LYR -0.73 总股本 7.23亿 股息收益率 -- 每股收益TTM -11.10 流通股本 7.23亿 ROA -15.64% 每股收益LYR -11.10 52周最高 52.600 ROE -534.39% 市净率 1.51，财报数据看着有点不好看"}],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":689128241,"gmtCreate":1655434200384,"gmtModify":1704862347210,"author":{"id":"3584009843426391","authorId":"3584009843426391","name":"___遇见倾橙____馨","avatar":"https://static.tigerbbs.com/5a3f250c18c42689db56196292cad8ab","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584009843426391","authorIdStr":"3584009843426391"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02137\">$腾盛博药-B(02137)$</a>现在止跌了，提前埋伏好来，这票出来这么多的利好消息，迟迟不涨，主力又在折磨人呢，大家得有耐心等待","listText":"<a href=\"https://laohu8.com/S/02137\">$腾盛博药-B(02137)$</a>现在止跌了，提前埋伏好来，这票出来这么多的利好消息，迟迟不涨，主力又在折磨人呢，大家得有耐心等待","text":"$腾盛博药-B(02137)$现在止跌了，提前埋伏好来，这票出来这么多的利好消息，迟迟不涨，主力又在折磨人呢，大家得有耐心等待","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":6,"repostSize":0,"link":"https://laohu8.com/post/689128241","isVote":1,"tweetType":1,"viewCount":1689,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000310","authorId":"9000000000000310","name":"迪士尼迪斯尼","avatar":"https://static.tigerbbs.com/d08ad56d0cf912758e58222fffc1f75b","crmLevel":1,"crmLevelSwitch":0,"idStr":"9000000000000310","authorIdStr":"9000000000000310"},"content":"总市值 58.9亿 成交量 364.00万 市盈率TTM -0.73 流通市值 58.9亿 股息 -- 市盈率LYR -0.73 总股本 7.23亿 股息收益率 -- 每股收益TTM -11.10 流通股本 7.23亿 ROA -15.64% 每股收益LYR -11.10 52周最高 52.600 ROE -534.39% 市净率 1.51，财报数据看着有点不好看","text":"总市值 58.9亿 成交量 364.00万 市盈率TTM -0.73 流通市值 58.9亿 股息 -- 市盈率LYR -0.73 总股本 7.23亿 股息收益率 -- 每股收益TTM -11.10 流通股本 7.23亿 ROA -15.64% 每股收益LYR -11.10 52周最高 52.600 ROE -534.39% 市净率 1.51，财报数据看着有点不好看","html":"总市值 58.9亿 成交量 364.00万 市盈率TTM -0.73 流通市值 58.9亿 股息 -- 市盈率LYR -0.73 总股本 7.23亿 股息收益率 -- 每股收益TTM -11.10 流通股本 7.23亿 ROA -15.64% 每股收益LYR -11.10 52周最高 52.600 ROE -534.39% 市净率 1.51，财报数据看着有点不好看"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":685975067,"gmtCreate":1659419949360,"gmtModify":1659419949360,"author":{"id":"3584009843426391","authorId":"3584009843426391","name":"___遇见倾橙____馨","avatar":"https://static.tigerbbs.com/5a3f250c18c42689db56196292cad8ab","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584009843426391","authorIdStr":"3584009843426391"},"themes":[],"htmlText":"这篇文章不错，转发给大家看","listText":"这篇文章不错，转发给大家看","text":"这篇文章不错，转发给大家看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/685975067","repostId":"682495624","repostType":1,"repost":{"id":682495624,"gmtCreate":1659098820000,"gmtModify":1659101103758,"author":{"id":"4088222930030430","authorId":"4088222930030430","name":"腾盛博药2137HK","avatar":"https://static.tigerbbs.com/7225daebeee9c083bcbed970259d2446","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4088222930030430","authorIdStr":"4088222930030430"},"themes":[],"title":"引领中国科技创新，腾盛博药被评为《麻省理工科技评论》50家聪明公司之一","htmlText":"7月29日，《麻省理工科技评论》2021年度50家聪明公司（TR50）榜单重磅揭晓，腾盛博药凭借其创新的研发管线，以及其在新冠中和抗体药物研发上的重大突破荣登榜单。此次年度榜单评选以“可持续未来”概念为导向，聚焦“在中国诞生的、由中国引领的、为中国服务”的创新力量，从而预见未来有能力引领中国和世界科技发展浪潮的企业。该榜单汇聚了在中国具有科技创新影响力，看重中国未来潜力，并且积极布局并服务中国市场的公司。腾盛博药自创立至今，始终践行以突破性的创新和洞察应对最严峻公共卫生挑战的使命，致力于针对患者未被满足的需求和重大公共卫生性疾病开发创新疗法。公司布局乙肝、新冠、艾滋病等多种重大传染性病领域。其中，其新冠中和抗体安巴韦单抗和罗米司韦单抗联合疗法作为中国首个获批的新冠中和抗体药物，仅用了27个月的时间就从最初的开发推进到商业化上市，为我国疫情防控做出重大贡献。《麻省理工科技评论》自1899年诞生起，长期关注创新科技的商业化和资本化进程，不仅见证了百年岁月中跌宕起伏的产业变迁，也参与了一代又一代新技术浪潮引发的时代变革。2010年开始，《麻省理工科技评论》每年都会从全球万千科技公司中遴选出“50 家聪明公司”（50 Smartest Companies，TR50），以此洞见未来科技大势。点击下图浏览完整榜单关于腾盛博药腾盛博药生物科技有限公司（“腾盛博药”；股份代号：2137.HK）是一家位于中国及美国的生物技术公司，致力于针对中国及全球重大感染性疾病（如乙型肝炎、COVID-19、人类免疫缺陷病毒 (HIV) 感染、多重耐药 (MDR) 或广泛耐药性 (XDR) 革兰氏阴性菌感染）及其它具有重大公共卫生负担的疾病（如中枢神经系统 (CNS) 疾病）开发创新疗法。阅读原文文章原文","listText":"7月29日，《麻省理工科技评论》2021年度50家聪明公司（TR50）榜单重磅揭晓，腾盛博药凭借其创新的研发管线，以及其在新冠中和抗体药物研发上的重大突破荣登榜单。此次年度榜单评选以“可持续未来”概念为导向，聚焦“在中国诞生的、由中国引领的、为中国服务”的创新力量，从而预见未来有能力引领中国和世界科技发展浪潮的企业。该榜单汇聚了在中国具有科技创新影响力，看重中国未来潜力，并且积极布局并服务中国市场的公司。腾盛博药自创立至今，始终践行以突破性的创新和洞察应对最严峻公共卫生挑战的使命，致力于针对患者未被满足的需求和重大公共卫生性疾病开发创新疗法。公司布局乙肝、新冠、艾滋病等多种重大传染性病领域。其中，其新冠中和抗体安巴韦单抗和罗米司韦单抗联合疗法作为中国首个获批的新冠中和抗体药物，仅用了27个月的时间就从最初的开发推进到商业化上市，为我国疫情防控做出重大贡献。《麻省理工科技评论》自1899年诞生起，长期关注创新科技的商业化和资本化进程，不仅见证了百年岁月中跌宕起伏的产业变迁，也参与了一代又一代新技术浪潮引发的时代变革。2010年开始，《麻省理工科技评论》每年都会从全球万千科技公司中遴选出“50 家聪明公司”（50 Smartest Companies，TR50），以此洞见未来科技大势。点击下图浏览完整榜单关于腾盛博药腾盛博药生物科技有限公司（“腾盛博药”；股份代号：2137.HK）是一家位于中国及美国的生物技术公司，致力于针对中国及全球重大感染性疾病（如乙型肝炎、COVID-19、人类免疫缺陷病毒 (HIV) 感染、多重耐药 (MDR) 或广泛耐药性 (XDR) 革兰氏阴性菌感染）及其它具有重大公共卫生负担的疾病（如中枢神经系统 (CNS) 疾病）开发创新疗法。阅读原文文章原文","text":"7月29日，《麻省理工科技评论》2021年度50家聪明公司（TR50）榜单重磅揭晓，腾盛博药凭借其创新的研发管线，以及其在新冠中和抗体药物研发上的重大突破荣登榜单。此次年度榜单评选以“可持续未来”概念为导向，聚焦“在中国诞生的、由中国引领的、为中国服务”的创新力量，从而预见未来有能力引领中国和世界科技发展浪潮的企业。该榜单汇聚了在中国具有科技创新影响力，看重中国未来潜力，并且积极布局并服务中国市场的公司。腾盛博药自创立至今，始终践行以突破性的创新和洞察应对最严峻公共卫生挑战的使命，致力于针对患者未被满足的需求和重大公共卫生性疾病开发创新疗法。公司布局乙肝、新冠、艾滋病等多种重大传染性病领域。其中，其新冠中和抗体安巴韦单抗和罗米司韦单抗联合疗法作为中国首个获批的新冠中和抗体药物，仅用了27个月的时间就从最初的开发推进到商业化上市，为我国疫情防控做出重大贡献。《麻省理工科技评论》自1899年诞生起，长期关注创新科技的商业化和资本化进程，不仅见证了百年岁月中跌宕起伏的产业变迁，也参与了一代又一代新技术浪潮引发的时代变革。2010年开始，《麻省理工科技评论》每年都会从全球万千科技公司中遴选出“50 家聪明公司”（50 Smartest Companies，TR50），以此洞见未来科技大势。点击下图浏览完整榜单关于腾盛博药腾盛博药生物科技有限公司（“腾盛博药”；股份代号：2137.HK）是一家位于中国及美国的生物技术公司，致力于针对中国及全球重大感染性疾病（如乙型肝炎、COVID-19、人类免疫缺陷病毒 (HIV) 感染、多重耐药 (MDR) 或广泛耐药性 (XDR) 革兰氏阴性菌感染）及其它具有重大公共卫生负担的疾病（如中枢神经系统 (CNS) 疾病）开发创新疗法。阅读原文文章原文","images":[{"img":"https://static.tigerbbs.com/d820fd0756294c92ba1a5a01063ce48f"},{"img":"https://static.tigerbbs.com/625356db2ee84948a5932a128615e8fd","width":"-1","height":"-1"},{"img":"https://static.tigerbbs.com/27a9fabd27f042e4a5125df29b901e14","width":"-1","height":"-1"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/682495624","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":5,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":987,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":683619409,"gmtCreate":1656297478603,"gmtModify":1704864345915,"author":{"id":"3584009843426391","authorId":"3584009843426391","name":"___遇见倾橙____馨","avatar":"https://static.tigerbbs.com/5a3f250c18c42689db56196292cad8ab","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584009843426391","authorIdStr":"3584009843426391"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02137\">$腾盛博药-B(02137)$</a>起飞了","listText":"<a href=\"https://laohu8.com/S/02137\">$腾盛博药-B(02137)$</a>起飞了","text":"$腾盛博药-B(02137)$起飞了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/683619409","isVote":1,"tweetType":1,"viewCount":571,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
